Nanoparticle Delivery of MnO 2 and Antiangiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma

Chih-Chun Chang,Trinh Kieu Dinh,Yi-An Lee,Fu-Nien Wang,Yun-Chieh Sung,Pei-Lun Yu,Shao-Chieh Chiu,Yu-Chuan Shih,Cheng-Yun Wu,Yi-Da Huang,Jane Wang,Tsai-Te Lu,Dehui Wan,Yunching Chen
DOI: https://doi.org/10.1021/acsami.0c08473
2020-08-31
Abstract:Antiangiogenic therapy is widely administered in many cancers, and the antiangiogenic drug sorafenib offers moderate benefits in advanced hepatocellular carcinoma (HCC). However, antiangiogenic therapy can also lead to hypoxia-driven angiogenesis and immunosuppression in the tumor microenvironment (TME) and metastasis. Here, we report the synthesis and evaluation of NanoMnSor, a tumor-targeted, nanoparticle drug carrier that efficiently codelivers oxygen-generating MnO<sub>2</sub> and sorafenib into HCC. We found that MnO<sub>2</sub> not only alleviates hypoxia by catalyzing the decomposition of H<sub>2</sub>O<sub>2</sub> to oxygen but also enhances pH/redox-responsive T1-weighted magnetic resonance imaging and drug-release properties upon decomposition into Mn<sup>2+</sup> ions in the TME. Moreover, macrophages exposed to MnO<sub>2</sub> displayed increased mRNA associated with the immunostimulatory M1 phenotype. We further show that NanoMnSor treatment leads to sorafenib-induced decrease in tumor vascularization and significantly suppresses primary tumor growth and distal metastasis, resulting in improved overall survival in a mouse orthotopic HCC model. Furthermore, NanoMnSor reprograms the immunosuppressive TME by reducing the hypoxia-induced tumor infiltration of tumor-associated macrophages, promoting macrophage polarization toward the immunostimulatory M1 phenotype, and increasing the number of CD8<sup>+</sup> cytotoxic T cells in tumors, thereby augmenting the efficacy of anti-PD-1 antibody and whole-cell cancer vaccine immunotherapies. Our study demonstrates the potential of oxygen-generating nanoparticles to deliver antiangiogenic agents, efficiently modulate the hypoxic TME, and overcome hypoxia-driven drug resistance, thereby providing therapeutic benefit in cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c08473?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c08473</a>.Profiles of hematologic parameters in mice treated with NanoMnSor; list of genes examined by RT-PCR and the primer sequences used; Fourier transform infrared analysis of lipid-coated MnO<sub>2</sub> cores; Fourier transform infrared analysis of tumor-targeted NanoMnSor modified with SP94 peptides; a representative TEM image of NanoMnSor; oxygen generation from NanoMn or NanoMnSor in a H<sub>2</sub>O<sub>2</sub> solution under pH 7.4 and 5.5; serum concentration profile of tumor-targeted MnO<sub>2</sub>-loaded PLGA NPs; tissue distribution of tumor-targeted MnO<sub>2</sub>-loaded PLGA NPs; representative immunofluorescence images of CD31, hypoxia, and TUNEL staining after NanoMnSor treatment; quantitative measures of hydroxyl radicals produced from the decomposition of hydrogen peroxide catalyzed by NanoMn; effects of hypoxia on M1 and M2 polarization in BMDMs; NanoMnSor-suppressed tumor growth in the orthotopic HCC model (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c08473/suppl_file/am0c08473_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
materials science, multidisciplinary,nanoscience & nanotechnology
What problem does this paper attempt to address?